- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05206916
New Procedures in Treating Patients With Obstructive Sleep Apnea Syndrome
January 12, 2022 updated by: Fatma hassanien mohamed, Sohag University
Evaluation of Novel Drug Induced Sleep Endoscopy Procedures in Treating Patients With Obstructive Sleep Apnea Syndrome
Drug-induced sleep endoscopy (DISE) used as diagnostic tool but not yet as a therapeutic procedures to manage the upper airway of snorers and obstructive sleep apnea patients in conditions that mimic natural sleep, there are many aspects that need to be standardized in order to obtain reliable and reproducible information result in cryotherapy at sites of vibration as origin of snoring and site of collapse.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: fatma h mohamed, assistant lecturer
- Phone Number: mobile 01093199561
- Email: fatma.hassanain@med.sohag.edu.eg
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 25 - 65 years.
- Diagnosed with mild, moderate to severe OSA based American Acadmey of Sleep Medicine (AASM) severity Index of apnea hypopnea index (AHI) after Polysomnography (AHI ≥ 5-15 mild, ≥15-30 moderate, ≥30 severe) based on a prior sleep study.
- BMI is between 28 kg/m2 and 40 kg/m2 at enrollment.
- Negative result for COVID-19 polymerase chain reaction (RT-PCR) test and absence of clinical symptoms for COVID-19.
Exclusion Criteria:
- Subjects with a high percentage of central apneas suggesting heart failure.
- Contraindication to general anesthesia or surgery.
- Craniofacial abnormality (e.g. retrognathia, micrognathia, etc.) thought to be the primary cause of OSA.
- Obvious fixed upper airway obstructions (tumors, polyps, nasal obstruction).
- Tonsil size ≥ +3.
- Previous surgery within 12 weeks of scheduled procedure performed on the soft tissue of the upper airway (e.g., uvula, soft palate or tonsils).
- Oral cancer or non-healing oral wounds.
- Presence of symptoms of influenza-like symptoms.
- History of surgery affecting the tongue [transoral robotic surgery (TORS), semi-glossectomy, radio-frequency ablation of base of tongue (RFBOT), maxillomandibular advancement (MMA), hypoglossal nerve stimulation (HGNS)].
- History of radiation therapy to neck or upper respiratory tract
- Surgical resection for cancer or congenital malformations in the larynx, tongue, or throat (with exception of tonsillectomy and/or adenoidectomy).
- Clinical evidence of severe chronic obstructive or restrictive pulmonary disease (for example chronic bronchitis, emphysema, pulmonary fibrosis).
- Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism).
- Currently receiving treatment for severe cardiac valvular dysfunction, new york heart association (NYHA) Class III or IV heart failure, unstable angina or recent (< 12 month) myocardial infarction or severe cardiac arrhythmias.
- Subjects with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months.
- Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 12 months.
- History or current clinical evidence of transient ischaemic attack (TIA) or stroke or muscular dysfunction.
- Taking medications that in the opinion of the consulting physician may alter consciousness, the pattern of respiration, or sleep architecture, such examples being benzodiazepines, opiates, neuroleptics, prescription stimulants, phenothiazine, or any form of chemical substance abuse.
- History of dementia or active psychiatric disease that may impact study compliance.
- Females who are pregnant or females of childbearing age with intention to become pregnant during the study period (≤ 3 months from treatment date).
- Unable and/or unwilling to comply with study requirements or to provide written informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: evaluation of cryotherapy as treatment for obstructive sleep apnea patients
|
Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
value, side effect and impact of cryotherapy in treatment of patients with obstructive sleep apnea syndrome
Time Frame: polysomnography will done after 2 weeks of intervention
|
we use drug induced sleep endoscopy during intervention and use polysomnography before the intervention as diagnostic for cases and after intervention for follow up of cases
|
polysomnography will done after 2 weeks of intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2022
Primary Completion (Anticipated)
May 1, 2023
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
January 12, 2022
First Submitted That Met QC Criteria
January 12, 2022
First Posted (Actual)
January 25, 2022
Study Record Updates
Last Update Posted (Actual)
January 25, 2022
Last Update Submitted That Met QC Criteria
January 12, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Soh-Med-21-12-22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea Syndrome
-
University of ChicagoGlaxoSmithKlineCompletedChildhood Obstructive Sleep Apnea Syndrome (OSAS)United States
-
University Hospital, GrenobleTerminatedChronic Obstructive Pulmonary Disease (COPD) | Obstructive Sleep Apnea Syndrome (OSAS)France
-
Royal College of Surgeons, IrelandUniversity College Dublin; Connolly Hospital BlanchardstownCompletedObstructive Sleep Apnoea SyndromeIreland
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingModerate Obstructive Sleep Apnea SyndromeFrance
-
Karolinska University HospitalCompletedObstructive Sleep Apnea Syndrome in ChildrenSweden
-
University of Alabama at BirminghamTerminatedObstructive Sleep Apnea Hypopnea Syndrome (OSAHS)United States
-
Sakarya UniversityUnknown
-
Haute Ecole de Santé VaudUnknownObstructive Sleep Apnea SyndromeSwitzerland
-
Karolinska University HospitalKarolinska InstitutetCompletedObstructive Sleep Apnea SyndromeSweden
-
Tyco Healthcare GroupUnknown
Clinical Trials on cryotherapy
-
Cairo UniversityNot yet recruiting
-
Creighton UniversityCompleted
-
Azienda Ospedaliera San Camillo ForlaniniCompleted
-
Hanyang University Seoul HospitalCompletedCryotherapy EffectKorea, Republic of
-
Ondokuz Mayıs UniversityRecruitingPain, Postoperative | Pulpitis | Caries; DentinTurkey
-
Entellus Medical, Inc.North American Science Associates Inc.Active, not recruiting
-
CSA Medical, Inc.WithdrawnLung Diseases, Obstructive | Airway Obstruction | Lung Disease Airways | Airway; Obstruction, With Emphysema
-
Unity Health TorontoRecruitingRetinal Detachment | MetamorphopsiaCanada
-
Flávia CarvalhoNot yet recruitingFunctional Status | Muscle Tone
-
H. Lee Moffitt Cancer Center and Research InstituteColumbia University; University Hospitals Cleveland Medical Center; Geisinger... and other collaboratorsSuspendedBleeding | GAVE - Gastric Antral Vascular Ectasia | Bleeding GastricUnited States